Clinical Translational Research

Esen S.A. · Ozgun Y.M. · Hasturk D. · Ucar G. · Bostanci E.B. · Sendur M. · Uncu D.

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details Abstract

Introduction: This study examined the difference in overall survival (OS) between peritoneal metastatic gastric cancer patients who underwent neoadjuvant chemotherapy followed by cytoreductive surgery±hyperthermic intraperitoneal chemotherapy (CRS±HIPEC) and those who did not have surgery but instead received palliative chemotherapy. Methods:This retrospective study included 80 patients who were followed up with the diagnosis of peritoneal metastatic gastric cancer, those undergoing neoadjuvant chemotherapy followed by CRS±HIPEC (CRS±HIPEC group) and those receiving chemotherapy only (non-surgical group), in the medical oncology clinic between April 2011 and December 2021. Clinicopathological features, treatments and OS of the patients were compared. Results:There were 32 patients in the SRC CRS±HIPEC group and 48 in the non-surgical group. In the CRS±HIPEC group, CRS+HIPEC was performed in 20 patients and only CRS was performed on 12 patients. All of the patients who underwent CRS+HIPEC, and 5 of the patients who underwent only CRS received neoadjuvant chemotherapy. While the median OS was 19.7 (15.5-23.8) months in the CRS±HIPEC group, the median OS was 6.8 (3.5-10.2) months in the non-surgical group (p

S. Karger AG, Basel

Article / Publication Details Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.